<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04536077</url>
  </required_header>
  <id_info>
    <org_study_id>202011125</org_study_id>
    <nct_id>NCT04536077</nct_id>
  </id_info>
  <brief_title>Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients</brief_title>
  <official_title>Testing the Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celldex Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Foundation for Barnes-Jewish Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The central hypothesis is that the addition of CDX-301 to CDX-1140 radically improves&#xD;
      anti-tumor immunity in patients with pancreatic ductal adenocarcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 25, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amount of intratumoral conventional dendritic cells between patients treated with CDX-1140 alone versus patients treated with CDX-301 plus CDX-1140</measure>
    <time_frame>At time of surgery (estimated to be between day 8 and day 20)</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Pancreatic Cancer</condition>
  <condition>Cancer of the Pancreas</condition>
  <condition>Pancreas Cancer</condition>
  <arm_group>
    <arm_group_label>CDX-1140 Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to the CDX-1140 monotherapy arm will receive a single IV infusion at a dose of 1.5 mg/kg, with surgery to follow 7-12 days after administration of CDX-1140.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CDX-1140 + CDX-301</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to the CDX-301 + CDX-1140 arm will receive CDX-301 at 75 mcg/kg/day as a subcutaneous injection every day for 5 days (Days 1-5) with CDX-1140 IV at 1.5 mg/kg on Day 8 +/-1 day. Surgery will be 7-12 days after administration of CDX-1140.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CDX-301</intervention_name>
    <description>The drug will be supplied free of charge by Celldex</description>
    <arm_group_label>CDX-1140 + CDX-301</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CDX-1140</intervention_name>
    <description>The drug will be supplied free of charge by Celldex</description>
    <arm_group_label>CDX-1140 + CDX-301</arm_group_label>
    <arm_group_label>CDX-1140 Monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Research blood draw</intervention_name>
    <description>At screening; prior to first therapeutic dose of CDX-1140, on the day of the infusion; and at the time of surgery</description>
    <arm_group_label>CDX-1140 + CDX-301</arm_group_label>
    <arm_group_label>CDX-1140 Monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed surgically resectable pancreatic ductal&#xD;
             adenocarcinoma, but not adenosquamous/squamous pancreas cancers (as determined by&#xD;
             operating surgeon or tumor board). Patients who have previously received chemotherapy&#xD;
             for his/her pancreas cancer within the past 6 months and who are now deemed resectable&#xD;
             are also eligible for this trial.&#xD;
&#xD;
          -  At least 18 years of age.&#xD;
&#xD;
          -  ECOG performance status ≤ 1&#xD;
&#xD;
          -  Normal bone marrow and organ function as defined below:&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 1,500 /cumm&#xD;
&#xD;
               -  Platelets ≥ 100,000 /cumm&#xD;
&#xD;
               -  Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
               -  AST(SGOT)/ALT(SGPT) ≤ 2.5 x IULN&#xD;
&#xD;
               -  Creatinine clearance ≤ 1.5 x IULN or glomerular filtration rate of ≥ 60 mL/min&#xD;
&#xD;
               -  INR ≤ 1.5 x IULN unless patient is receiving anticoagulant therapy as long as INR&#xD;
                  or PTT is within therapeutic range of intended use of anticoagulants&#xD;
&#xD;
               -  aPTT ≤ 1.5 x IULN unless patient is receiving anticoagulant therapy as long as&#xD;
                  INR or PTT is within therapeutic range of intended use of anticoagulants&#xD;
&#xD;
               -  Albumin ≥ 3.0mg/dL&#xD;
&#xD;
          -  The effects of CDX-301 and CDX-1140 on the developing human fetus are unknown. For&#xD;
             this reason, women of childbearing potential and men must agree to use adequate&#xD;
             contraception (hormonal or barrier method of birth control, abstinence) prior to study&#xD;
             entry, for the duration of study participation, and for 3 months after the last dose&#xD;
             of either study drug. Should a woman become pregnant or suspect she is pregnant while&#xD;
             participating in this study or for 3 months after the last dose of either study drug,&#xD;
             she must inform her treating physician immediately.&#xD;
&#xD;
          -  Ability to understand and willingness to sign an IRB approved written informed consent&#xD;
             document (or that of legally authorized representative, if applicable).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Immune deficiencies such as HIV.&#xD;
&#xD;
          -  A history of other malignancy with the exception of malignancies for which all&#xD;
             treatment was completed at least 2 years before registration and the patient has no&#xD;
             evidence of disease.&#xD;
&#xD;
          -  Currently receiving any other investigational agents or has received any other&#xD;
             investigational agents within 4 weeks or 5 half-lives of the planned first dose of&#xD;
             study treatment.&#xD;
&#xD;
          -  Receipt of chemotherapy within 2 weeks of planned first dose of study treatment.&#xD;
&#xD;
          -  A history of allergic reactions attributed to compounds of similar chemical or&#xD;
             biologic composition to CDX-301 or CDX-1140 or other agents used in the study.&#xD;
&#xD;
          -  Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy&#xD;
             (for &gt; 1 month of 10 mg prednisone daily, or equivalent) or any other form of&#xD;
             immunosuppressive therapy not routinely associated with chemotherapeutic regimen.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, immunosuppression, autoimmune conditions, or underlying pulmonary disease.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, immunosuppression, autoimmune conditions, or underlying pulmonary disease.&#xD;
&#xD;
          -  Has an autoimmune disease requiring systemic treatment within the past 2 years (i.e.&#xD;
             with use of disease modifying agents, corticosteroids, or immunosuppressive drugs).&#xD;
             Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid&#xD;
             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a&#xD;
             form of systemic treatment.&#xD;
&#xD;
          -  Known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive)&#xD;
             or known active hepatitis C virus (defined as HCV RNA [qualitative] is detected).&#xD;
&#xD;
          -  Has a history of (non-infectious) pneumonitis that required steroids or current&#xD;
             pneumonitis.&#xD;
&#xD;
          -  Has a known history of active TB (bacillus tuberculosis).&#xD;
&#xD;
          -  Major surgery within 28 days prior to the first study treatment.&#xD;
&#xD;
          -  Pregnant and/or breastfeeding. Women of childbearing potential must have a negative&#xD;
             pregnancy test within 14 days of study entry.&#xD;
&#xD;
          -  History of bone marrow or solid organ transplant.&#xD;
&#xD;
          -  Patients with a history of myocardial infarction, cerebral vascular accident,&#xD;
             thrombosis or pulmonary embolus within 12 months prior to the first dose of study&#xD;
             treatment are excluded from this study.&#xD;
&#xD;
          -  Patients with known mutations/amplifications in Flt3&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William G Hawkins, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>William G Hawkins, M.D.</last_name>
    <phone>314-362-7046</phone>
    <email>hawkinsw@wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William G Hawkins, M.D.</last_name>
      <phone>314-362-7046</phone>
      <email>hawkinsw@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>William G Hawkins, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David DeNardo, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ryan Fields, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kian-Huat Lim, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivia Aranha, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nusayba Bagegni, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Salman Chaudhry, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick Grierson, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tanner Johanns, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Knoche, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Haeseong Park, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katrina Pedersen, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rama Suresh, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benjamin Tan, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nikolaos Trikalinos, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Liang Kang, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Deyali Chatterjee, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 27, 2020</study_first_submitted>
  <study_first_submitted_qc>August 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2020</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

